321 related articles for article (PubMed ID: 24861776)
1. Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
Brufsky AM
Breast J; 2014; 20(4):347-57. PubMed ID: 24861776
[TBL] [Abstract][Full Text] [Related]
2. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
3. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
4. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Ciruelos Gil EM
Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
[TBL] [Abstract][Full Text] [Related]
5. [Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer].
; ; ;
Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):673-692. PubMed ID: 35880333
[TBL] [Abstract][Full Text] [Related]
6. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
7. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Araki K; Miyoshi Y
Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Zardavas D; Fumagalli D; Loi S
Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
[TBL] [Abstract][Full Text] [Related]
11. Everolimus in the treatment of hormone receptor-positive breast cancer.
Chavez-MacGregor M; Gonzalez-Angulo AM
Expert Opin Investig Drugs; 2012 Dec; 21(12):1835-43. PubMed ID: 22994502
[TBL] [Abstract][Full Text] [Related]
12. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
[TBL] [Abstract][Full Text] [Related]
13. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
14. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
Barrett D; Brown VI; Grupp SA; Teachey DT
Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
[TBL] [Abstract][Full Text] [Related]
15. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibitors in advanced breast cancer: ready for prime time?
Martin LA; André F; Campone M; Bachelot T; Jerusalem G
Cancer Treat Rev; 2013 Nov; 39(7):742-52. PubMed ID: 23557794
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
Han Y; Wang J; Wang Z; Xu B
Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
[TBL] [Abstract][Full Text] [Related]
18. PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects.
Miricescu D; Totan A; Stanescu-Spinu II; Badoiu SC; Stefani C; Greabu M
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375317
[TBL] [Abstract][Full Text] [Related]
19. [Antihormonal therapy in breast cancer and mTOR inhibitors].
Heudel PÉ; Tredan O; Ray-Coquard I; Treilleux I; Guastalla JP; Bachelot T
Bull Cancer; 2011 Dec; 98(12):1431-7. PubMed ID: 22133994
[TBL] [Abstract][Full Text] [Related]
20. Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway.
Wilks ST
Breast; 2015 Oct; 24(5):548-55. PubMed ID: 26187798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]